Annovis Bio, Inc.
Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Its lead candidate, buntanetap, is an oral small molecule designed to reduce the production of multiple neurotoxic proteins; the company… From the company’s description.
In fiscal 2025, Annovis Bio, Inc. reported a net loss of $28.85M. Operations used $25.62M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Annovis Bio, Inc. does
In the company’s own words
Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Its lead candidate, buntanetap, is an oral small molecule designed to reduce the production of multiple neurotoxic proteins; the company is testing it in a Phase 3 Alzheimer’s study and a long-term Parkinson’s disease study, and is planning a program for Parkinson’s disease dementia. Annovis also develops ANVS405, an intravenous candidate for acute brain injury, including traumatic brain injury and stroke, and ANVS301, an oral candidate for later-stage Alzheimer’s disease and dementia. The company’s research focuses on a platform intended to target several neurotoxic proteins and address nerve-cell function across multiple conditions. It reports that more than 1,200 people have received buntanetap in clinical studies. Annovis has no reportable operating segments described in its business overview.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MALVERN, PA
- Fiscal year end
- December
- CIK
- 1477845
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Annovis Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Annovis Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Annovis Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Annovis Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Annovis Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”